Sagimet Biosciences Inc (SGMT)
3.97
-0.25
(-5.92%)
USD |
NASDAQ |
Jun 18, 16:00
3.97
0.00 (0.00%)
After-Hours: 18:22
Sagimet Biosciences Cash from Financing (Quarterly): 104.85M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 104.85M |
December 31, 2023 | 0.00 |
September 30, 2023 | 87.21M |
June 30, 2023 | -0.91M |
March 31, 2023 | -0.136M |
December 31, 2022 | -0.055M |
Date | Value |
---|---|
September 30, 2022 | 0.00 |
June 30, 2022 | -0.03M |
March 31, 2022 | 0.012M |
March 31, 2021 | 11.14M |
March 31, 2020 | 0.00 |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.91M
Minimum
Jun 2023
104.85M
Maximum
Mar 2024
18.37M
Average
--
Median
Mar 2020
Cash from Financing (Quarterly) Benchmarks
Eli Lilly and Co | -311.30M |
Ionis Pharmaceuticals Inc | 23.57M |
Madrigal Pharmaceuticals Inc | 573.71M |
Galectin Therapeutics Inc | 10.00M |
Hepion Pharmaceuticals Inc | 1.850M |
Cash from Financing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -6.208M |
Cash from Investing (Quarterly) | 3.00M |
Free Cash Flow | -22.89M |
Free Cash Flow Per Share (Quarterly) | -0.2138 |
Free Cash Flow Yield | -24.99% |